[Comparative study of the smallpox vaccines from B-51, EM-63 and L-IVP in a controlled epidemiological experiment. II. The characteristiics of the immunogenicity of the smallpox vaccines]. 1978

G N Khliabich, and A A Sumarokov, and G A Karinskaia, and R Ia Shkol'nik, and N V Iaroslavskaia

Immunogenicity of smallpox vaccines prepared of EM-63, L-IVP, and B-51 strains was studied under conditions of strict controlled epidemiological trial. Skin reactions to revaccination and vaccines antigenic activity indices were detemined in the persons vaccinated. Changes in the virus-neutralizing and antibodies suppressing hemagglutination was the same in persons vaccinated with any of the preparations tested. The maximal virus-neutralizing antibodies level was determined 1 month after the vaccination and persisted without any essential changes for one year. The titre of hemagglutination inhibiting antibodies also reached the maximum in one month, but diminished gradually by the end of one year after the vaccination. There were found no significant differences in the antigenic activity of the vaccines. The vaccines studied also displayed no difference in the number and character of skin reactions to revaccination. In comparing the antibodies level and the character of skin reactions to revaccination it was found that the titres of hemagglutination inhibiting antibodies and virus-neutralizing antibodies of 1:40 and over were in the great majority of cases determined in the blood sera of the vaccinated persons with the immediate and negative reactions to revaccination, i. e. in those with intensive postvaccinal immunity.

UI MeSH Term Description Entries
D007109 Immunity Nonsusceptibility to the invasive or pathogenic effects of foreign microorganisms or to the toxic effect of antigenic substances. Immune Process,Immune Response,Immune Processes,Immune Responses,Process, Immune,Response, Immune
D007117 Immunization, Secondary Any immunization following a primary immunization and involving exposure to the same or a closely related antigen. Immunization, Booster,Revaccination,Secondary Immunization,Booster Immunization,Booster Immunizations,Immunizations, Booster,Immunizations, Secondary,Revaccinations,Secondary Immunizations
D007223 Infant A child between 1 and 23 months of age. Infants
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D006385 Hemagglutination Inhibition Tests Serologic tests in which a known quantity of antigen is added to the serum prior to the addition of a red cell suspension. Reaction result is expressed as the smallest amount of antigen which causes complete inhibition of hemagglutination. Hemagglutination Inhibition Test,Inhibition Test, Hemagglutination,Inhibition Tests, Hemagglutination,Test, Hemagglutination Inhibition,Tests, Hemagglutination Inhibition
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies

Related Publications

G N Khliabich, and A A Sumarokov, and G A Karinskaia, and R Ia Shkol'nik, and N V Iaroslavskaia
January 1959, Bulletin of the World Health Organization,
G N Khliabich, and A A Sumarokov, and G A Karinskaia, and R Ia Shkol'nik, and N V Iaroslavskaia
January 1971, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
G N Khliabich, and A A Sumarokov, and G A Karinskaia, and R Ia Shkol'nik, and N V Iaroslavskaia
October 1990, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
G N Khliabich, and A A Sumarokov, and G A Karinskaia, and R Ia Shkol'nik, and N V Iaroslavskaia
January 1972, Acta microbiologica Academiae Scientiarum Hungaricae,
G N Khliabich, and A A Sumarokov, and G A Karinskaia, and R Ia Shkol'nik, and N V Iaroslavskaia
January 1987, Postgraduate medical journal,
G N Khliabich, and A A Sumarokov, and G A Karinskaia, and R Ia Shkol'nik, and N V Iaroslavskaia
January 1972, Medicina,
G N Khliabich, and A A Sumarokov, and G A Karinskaia, and R Ia Shkol'nik, and N V Iaroslavskaia
June 1989, Vaccine,
G N Khliabich, and A A Sumarokov, and G A Karinskaia, and R Ia Shkol'nik, and N V Iaroslavskaia
January 1993, Voprosy virusologii,
G N Khliabich, and A A Sumarokov, and G A Karinskaia, and R Ia Shkol'nik, and N V Iaroslavskaia
February 1970, Zeitschrift fur die gesamte Hygiene und ihre Grenzgebiete,
Copied contents to your clipboard!